about
Successful treatment of high-grade pancreatic neuroendocrine neoplasms with everolimus.Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.An Advanced well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
@en
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
@nl
type
label
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
@en
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
@nl
prefLabel
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
@en
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
@nl
P2093
P1433
P1476
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
@en
P2093
Francesca Spada
Francesco Panzuto
Gianfranco Delle Fave
Lorenzo Antonuzzo
Maria Rinzivillo
Toni Ibrahim
P304
P356
10.1097/MPA.0000000000000762
P577
2017-01-18T00:00:00Z